Trials / Terminated
TerminatedNCT00202995
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glatiramer Acetate | 20 mg s.c. daily |
| DRUG | Betaseron | 250 mg every other day |
| DRUG | Rebif | 44 ug 3 times a week |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-09-20
- Last updated
- 2010-10-18
Source: ClinicalTrials.gov record NCT00202995. Inclusion in this directory is not an endorsement.